Highlights Median Technologies

Equities

ALMDT

FR0011049824

Real-time Euronext Paris Other stock markets 04:53:28 2024-04-29 am EDT			5-day change	1st Jan Change
2.79 ^EUR	-7.00%		-19.48%	-41.26%

2023	European Investment Bank OKs Median Technologies' Draw Down of Final EUR8.5 Million Loan Tranche	MT
2023	Median: final tranche of EIB loan approved	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Median: final tranche of EIB loan approved	Dec. 27	CF
Median Technologies and Pasrel-Imagerie Join Forces to Deliver Smart Imaging Biomarkers Supporting the Development of New Oncology Drugs in Precision Medicine	Dec. 14	CI
Median Technologies SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-18	CI
Median Technologies's iBiopsy HCC Detection AI Model Developed on the PHELICAR Clinical Data Registry, to Be Presented at the ESMO Congress	23-10-17	CI
Median Technologies Announces Onboarding of All Academic Sites Involved in the Pivotal Validation Plan for iBiopsy® LCS CADe/CADx SaMD	23-07-17	CI
Median Technologies SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-24	CI
Median Technologies SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-24	CI
Median Technologies to Present New and Breakthrough Results for its iBiopsy Lung Cancer Screening CADe/CADx Software as Medical Device	23-02-28	CI
Median Technologies Announces Completion of the Q-Submission Phase with the FDA for Its iBiopsy Lung Cancer Screening CADe/CADx Software as Medical Device	23-02-27	CI
Median Technologies SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-10-20	CI
Median Technologies SA Launches Imaging Lab, Spearheading the Integration of iBiopsy® Artificial Intelligence Technologies Into iCRO Imaging Services for Oncology Trials	22-05-31	CI
Median Technologies SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-21	CI
Median Technologies Announces Design Completion of its iBiopsy® Lung Cancer Screening End-to-end CADe/CADx Software	22-03-22	CI
Median Technologies SA Files FDA 513(g) Regulatory Submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device	22-03-03	CI
Median Technologies Announces New Outstanding Performance for Its iBiopsy? Lung Cancer Screening CADx With a Focus on Stage 1 Lung Cancer Characterization	21-11-23	CI
Median Technologies SA Reports Earnings Results for the Half Year Ended June 30, 2021	21-10-21	CI
Median Technologies Announces Outstanding Performance for Its iBiopsy® Lung Cancer Screening CADx to Accurately Characterize Malignant Vs Benign Lung Nodules Based on a Large-scale Patient Cohort	21-09-06	CI
Median Technologies Sa Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-08	CI
Median Technologies Sa Unveils New iBiopsy® Clinical Development Plan on Lung Cancer Screening	21-02-16	CI
Median Technologies Inks Major Research Collaboration Agreement With the University of California San Diego	21-02-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Median Technologies

Equities

ALMDT

FR0011049824

Highlights

Filters